Becton, Dickinson and Company (BDX)
After hours:
| Previous close | 232.78 |
| Open | 234.78 |
| Bid | 230.00 x 800 |
| Ask | 242.99 x 1200 |
| Day's range | 232.38 - 239.22 |
| 52-week range | 218.75 - 284.48 |
| Volume | |
| Avg. volume | 1,510,274 |
| Market cap | 68.581B |
| Beta (5Y monthly) | 0.44 |
| PE ratio (TTM) | 50.81 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.80 (1.60%) |
| Ex-dividend date | 09 Sept 2024 |
| 1y target est | N/A |
- PR Newswire
BD, Quest Diagnostics Join Forces to Develop Companion Diagnostics for Cancer, Other Diseases
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced a global collaboration agreement to develop, manufacture and commercialize flow cytometry-based companion diagnostics (CDx) intended to help select the best treatment for patients with cancer and other diseases.
- PR Newswire
BD Board Declares Dividend
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $0.95 per common share, payable on September 30, 2024 to holders of record on September 9, 2024. The indicated annual dividend rate is $3.80 per share.
- PR Newswire
BD Statement on Supplier Issue Impacting BD BACTEC™ Blood Culture Vials
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement related to a U.S. FDA letter to health care providers regarding the supply of blood culture vials:
